On or before December 1, 2023, the Board, in consultation with the Stakeholder Council, shall report to the Senate Finance Committee and the House Health and Government Operations Committee, in accordance with § 2–1257 of the State Government Article, on:
(1) The legality, obstacles, and benefits of setting upper payment limits on all purchases and payor reimbursements of prescription drug products in the State; and
(2) Recommendations regarding whether the General Assembly should pass legislation to expand the authority of the Board to set upper payment limits to all purchases and payor reimbursements of prescription drug products in the State.
Structure Maryland Statutes
Title 21 - Food, Drugs, and Cosmetics
Subtitle 2C - Prescription Drug Affordability Board
Section 21-2C-01 - Definitions
Section 21-2C-02 - Prescription Drug Affordability Board
Section 21-2C-04 - Prescription Drug Affordability Stakeholder Council
Section 21-2C-05 - Disclosure of Conflicts of Interest
Section 21-2C-06 - Acceptance of Gratuities Prohibited
Section 21-2C-08 - Collection, Review, and Use of Transparency Data for Prescription Drug Products
Section 21-2C-09 - Cost Review of Prescription Drug Products With Affordability Challenges
Section 21-2C-10 - Confidentiality
Section 21-2C-11 - Funding Source
Section 21-2C-12 - Enforcement
Section 21-2C-14 - Setting Upper Payment Limits for Prescription Drug Products